SynLaia is developing patient-centric target discovery and validation platform, designed to optimise and validate therapeutic opportunities by incorporating tissue-scale disease insights, mechanobiology and  in silico tissue mechanics. 

Unlike standard target discovery relying on genetic predictions from single-cell technologies,  we obtain spatial multi-modal omics data from human samples for direct translation within the correct tissue context. This high-throughput, reproducible method identifies biomarkers and drug targets by analysing changes in tissue mechanics and molecular profiles, focusing on therapeutic targets which are drivers of tissue mechanical states.